{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:15:15Z","timestamp":1772118915793,"version":"3.50.1"},"reference-count":36,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"DOI":"10.1210\/jc.2006-2283","type":"journal-article","created":{"date-parts":[[2007,2,28]],"date-time":"2007-02-28T03:00:38Z","timestamp":1172631638000},"page":"1803-1808","source":"Crossref","is-referenced-by-count":16,"title":["Increased Osteoprotegerin Levels in Cushing\u2019s Syndrome Are Associated with an Adverse Cardiovascular Risk Profile"],"prefix":"10.1210","volume":"92","author":[{"given":"Andrea","family":"Dovio","sequence":"first","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Allasino","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Palmas","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Ventura","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pia","sequence":"additional","affiliation":[{"name":"Endocrinologia (A.P.), Azienda Sanitaria Ospedaliera Santa Croce e Carle, I-12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Saba","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Aroasio","sequence":"additional","affiliation":[{"name":"Laboratorio Analisi (E.A.), Azienda Sanitaria Ospedaliera San Luigi, I-10043 Orbassano-Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Angeli","sequence":"additional","affiliation":[{"name":"Medicina Interna I (A.D., B.A., E.P., M.V., L.S., M.T., A.A.), Dipartimento di Scienze Cliniche e Biologiche, Universita\u0300 di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041114022448300_R1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases.","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114022448300_R2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling.","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"key\n\t\t\t\t2019041114022448300_R3","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating osteoprotegerin and receptor activator for nuclear factor \u03baB ligand: clinical utility in metabolic bone disease assessment.","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10 Suppl","key":"key\n\t\t\t\t2019041114022448300_R4","first-page":"14","article-title":"Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice","volume":"28","author":"Dovio","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041114022448300_R5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t2019041114022448300_R6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE\u2212\/\u2212 mice.","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041114022448300_R7","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement.","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114022448300_R8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: an update.","volume":"17","author":"Mazziotti","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114022448300_R9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1677\/joe.0.1770109","article-title":"Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines.","volume":"177","author":"Dovio","year":"2003","journal-title":"J Endocrinol"},{"key":"key\n\t\t\t\t2019041114022448300_R10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S8756-3282(02)00742-1","article-title":"Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.","volume":"30","author":"Sasaki","year":"2002","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114022448300_R11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00042737-200311000-00003","article-title":"Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn\u2019s disease.","volume":"15","author":"Tirpitz","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041114022448300_R12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/eje.0.1480527","article-title":"Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.","volume":"148","author":"Valleala","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114022448300_R13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/eje.0.1450685","article-title":"Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess\u2014possible role in bone homeostasis.","volume":"145","author":"Ueland","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114022448300_R14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/eje.1.02042","article-title":"Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing\u2019s syndrome.","volume":"153","author":"Reimondo","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114022448300_R15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114022448300_R16","unstructured":"http:\/\/www.sisalombardia.it\/; last access 06.09.06"},{"key":"key\n\t\t\t\t2019041114022448300_R17","first-page":"1011","article-title":"Guidelines for the management of arterial hypertension.","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019041114022448300_R18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.","volume":"20","year":"1997","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041114022448300_R19","first-page":"631","article-title":"Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.","volume":"86","author":"Browner","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114022448300_R20","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041114022448300_R21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ecl.2005.01.010","article-title":"The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome.","volume":"34","author":"Pivonello","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key\n\t\t\t\t2019041114022448300_R22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0021-9150(01)00487-7","article-title":"Cortisol in urine and saliva: relations to the intima media thickness, IMT.","volume":"159","author":"Hurwitz Eller","year":"2001","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t2019041114022448300_R23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/jcem.87.3.8277","article-title":"Adrenal incidentaloma: a new cause of the metabolic syndrome?","volume":"87","author":"Terzolo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114022448300_R24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.vph.2004.11.008","article-title":"Isoform-specific modulation of coronary artery PKC by glucocorticoids.","volume":"42","author":"Maddali","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"key\n\t\t\t\t2019041114022448300_R25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.20050119","article-title":"11\u03b2-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.","volume":"202","author":"Hermanowski-Vosatka","year":"2005","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019041114022448300_R26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2029","article-title":"MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis.","volume":"5","author":"Morand","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019041114022448300_R27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1359\/jbmr.060310","article-title":"Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis.","volume":"21","author":"Onodera","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114022448300_R28","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114022448300_R29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ghir.2004.06.002","article-title":"Bone metabolism in relation to alterations in systemic growth hormone.","volume":"14","author":"Ueland","year":"2004","journal-title":"Growth Horm IGF Res"},{"key":"key\n\t\t\t\t2019041114022448300_R30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00125-004-1652-8","article-title":"Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-\u03b1.","volume":"48","author":"Olesen","year":"2005","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t2019041114022448300_R31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00198-004-1699-x","article-title":"Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.","volume":"16","author":"Indridason","year":"2005","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114022448300_R32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1359\/jbmr.1999.14.4.518","article-title":"Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.","volume":"14","author":"Yano","year":"1999","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114022448300_R33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s001980200045","article-title":"Correlates of osteoprotegerin levels in women and men.","volume":"13","author":"Khosla","year":"2002","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114022448300_R34","first-page":"3162","article-title":"Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.","volume":"86","author":"Szulc","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114022448300_R35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00198-004-1616-3","article-title":"Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing\u2019s syndrome.","volume":"15","author":"Minetto","year":"2004","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114022448300_R36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.50.1","article-title":"Osteoporosis is more prevalent in adrenal than in pituitary Cushing\u2019s syndrome.","volume":"50","author":"Ohmori","year":"2003","journal-title":"Endocr J"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/5\/1803\/9054015\/jcem1803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:03:12Z","timestamp":1556150592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/5\/1803\/2598655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-2283","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}